A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
← catalyst calendarNCT06311721 · readout in 509 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
315actual
Sites
218
Countries
Argentina, Austria, Brazil +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-09 | actual | When the study began enrolling |
| Primary completion | 2028-01-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-24 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Interventions
- Drug: ABP 234
- Drug: Pembrolizumab (US) — also filed as Keytruda®
- Drug: Pembrolizumab (EU) — also filed as Keytruda®
Primary outcomes
what the primary-completion date above is the date OFArea under the serum concentration-time curve (AUC) from time 0 to 21 days (AUC21d) of ABP 234
measured 21 days
AUC21d of pembrolizumab (US)
measured 21 days
AUC21d of pembrolizumab (EU)
measured 21 days
AUC at steady state between Week 16 and Week 19 (AUCtau_ss) of ABP 234
measured Week 16 through Week 19
AUCtau_ss of pembrolizumab (US)
measured Week 16 through Week 19
AUCtau_ss of pembrolizumab (EU)
measured Week 16 through Week 19
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed